Related Experiment Video
Updated: Jul 2, 2025
Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
Importance of B-Type Natriuretic Peptide in the Detection of Patients With Structural Heart Disease in a Primary Care
Wataru Fujimoto1,2, Susumu Odajima2, Hiroshi Okamoto3
1Division of Cardiovascular Medicine, Hyogo Prefectural Awaji Medical Center.
Insights
Early detection of preclinical heart failure (HF) is vital. Measuring B-type natriuretic peptide (BNP) effectively identifies patients with early HF in primary care, aiding proactive intervention.
Area of Science:
- Cardiology
- Primary Care Medicine
- Biomarker Research
Background:
- Heart failure (HF) poses a growing global health challenge.
- Early detection and intervention are critical to manage HF progression.
- Preclinical HF detection is essential in primary care settings.
Purpose of the Study:
- To evaluate the efficacy of B-type natriuretic peptide (BNP) for early detection of preclinical HF.
- To assess BNP's role in identifying HF risk in a primary care population.
Main Methods:
- Retrospective cohort study of 477 patients without prior HF diagnosis.
- Patients categorized into four groups based on BNP levels (0-35, 35-100, 100-200, >200 pg/mL).
- Prevalence and odds ratios of preclinical HF were analyzed across BNP categories.
Main Results:
- Prevalence of preclinical HF significantly increased with higher BNP categories (19.9% to 96.0%).
- Odds ratios for preclinical HF were substantially elevated in higher BNP groups (5.56 to 171.77 compared to the lowest category).
- BNP levels strongly correlated with preclinical HF prevalence.
Conclusions:
- B-type natriuretic peptide (BNP) is a valuable tool for early preclinical HF detection in primary care.
- Proactive BNP testing in high-risk individuals can help address the HF pandemic.
- This study supports the integration of BNP measurement into routine primary care for HF screening.
Background:
Early detection and intervention for preclinical heart failure (HF) are crucial for restraining the potential increase in patients with HF. Thus, we designed and conducted a single-center retrospective cohort study to confirm the efficacy of B-type natriuretic peptide (BNP) for the early detection of preclinical HF in a primary care setting.
Methods And Results:
We investigated 477 patients with no prior diagnosis of HF who were under the care of general practitioners. These patients were categorized into 4 groups based on BNP concentrations: Category 1, 0 pg/mL≤BNP≤35 pg/mL; Category 2, 35 pg/mL
Conclusions:
Measuring BNP is a valuable tool for the early detection of preclinical HF in primary care settings. Proactive testing in patients at high risk of HF could play a crucial role in addressing the impending HF pandemic.
More Related Videos
10:33Assessment of Right Ventricular Structure and Function in Mouse Model of Pulmonary Artery Constriction by Transthoracic Echocardiography
Published on: February 3, 2014
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...